Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Erlotinib vs Tarceva in Healthy Subjects
NCT04145570Phase 4Completed
- Start
- Oct 2008
- Primary completion
- Nov 2008
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial of erlotinib in lung cancer (2 arms). Primary endpoint: Bioequivalence (Biodisponibility) at 72 hours. Started Oct 2008; status: completed.
02
Drugs
erlotinib
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT04145570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04145570.